Literature DB >> 7041944

Mycobacterium bovis, BCG, modulation of murine antibody responses: influence of dose and degree of aggregation of live or dead organisms.

C A Brown, I N Brown.   

Abstract

Mycobacteria have the ability to enhance or depress immune responses. This paper describes experiments designed to investigate the parameters determining the direction of modulation. It has been shown previously that 10(8) liver Mycobacterium bovis BCG depress the ability of mouse spleen cells to produce a primary antibody response in vitro to SRBC 2-3 weeks after i.v. injection, whereas the same number of dead organisms enhance this response. Using the same growth medium for the BCG (Glaxo glycerol-free medium), we now find that decreasing the BCG dose to mice from 10(8) to 10 (6) liver organisms results in enhanced responses and increasing the dose to more than 10(8) dead organisms results in depressed responses. It thus appears that bacterial load is the important factor determining whether depression or enhancement of the primary antibody response will occur, rather than the viability of the organisms per se. However, when the BCG was grown in Middlebrook 7H9 broth, doses as high as 4 X 10(9) dead BCG/mouse failed to depress although depressed responses were found if sufficient live organisms (7 X 10(8)) were injected. In view of the known growth characteristics of BCG in these 2 bacteriological media, it is suggested that the degree of aggregation of the injected suspension may also be of importance in determining whether or not depression will occur. A comparison of the effects of BCG injected untreated or after dispersion of bacterial aggregates supports this idea. Some degree of splenomegaly was always found in mice with depressed splenic responses but a large spleen did not necessarily yield cell suspensions with depressed responses.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7041944      PMCID: PMC2040605     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  19 in total

1.  BCG-induced suppressor cells. I. Demonstration of a macrophage-like suppressor cell that inhibits cytotoxic T cell generation in vitro.

Authors:  G R Klimpel; C S Henney
Journal:  J Immunol       Date:  1978-02       Impact factor: 5.422

2.  Immunopotentiation with BCG. I. Immune response to different strains and preparations.

Authors:  G B Mackaness; D J Auclair; P H Lagrange
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

Review 3.  Facilitation and inhibition of b16 melanoma by BCG in vivo and by lymphoid cells from bcg-treated mice in vitro.

Authors:  D O Chee; A J Bodurtha
Journal:  Int J Cancer       Date:  1974-07-15       Impact factor: 7.396

4.  Primary immune response in cultures of spleen cells.

Authors:  J Marbrook
Journal:  Lancet       Date:  1967-12-16       Impact factor: 79.321

5.  Suppressed or enhanced antibody responses in vitro after BCG treatment of mice: importance of BCG viability.

Authors:  C A Brown; I N Brown; V S Sljivić
Journal:  Immunology       Date:  1979-11       Impact factor: 7.397

6.  The host response to Calmette-Guérin bacillus infection in mice.

Authors:  R V Blanden; M J Lefford; G B Mackaness
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

7.  Further improvements in the plaque technique for detecting single antibody-forming cells.

Authors:  A J Cunningham; A Szenberg
Journal:  Immunology       Date:  1968-04       Impact factor: 7.397

8.  Genetic basis of BCG-induced suppression of delayed hypersensitivity.

Authors:  D J Schrier; J L Sternick; E M Allen; V L Moore
Journal:  Nature       Date:  1981-01-29       Impact factor: 49.962

9.  Stimulation of macrophages by cord factor and by heat-killed and living BCG.

Authors:  E Yarkoni; L Wang; A Bekierkunst
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

10.  Depressive effect of serum from patients with leprosy on mixed lymphocyte reactions. Influence of anti-leprosy treatment.

Authors:  D S Nelson; J M Penrose; M F Waters; J M Pearson; M Nelson
Journal:  Clin Exp Immunol       Date:  1975-12       Impact factor: 4.330

View more
  5 in total

1.  Generalised non-reactive tuberculosis: a clinicopathological study of four patients.

Authors:  R Singh; R C Joshi; J Christie
Journal:  Thorax       Date:  1989-11       Impact factor: 9.139

2.  Immunoresponses to Neisseria meningitidis epitopes: primary versus secondary antiphosphorylcholine responses.

Authors:  J Faro; R Seoane; E Puentes; F Martínez Ubeira; B J Regueiro
Journal:  Infect Immun       Date:  1985-05       Impact factor: 3.441

3.  Bacille Calmette-Guérin (BCG)-associated inflammation and fibrosis: modulation by recombinant BCG expressing interferon-gamma (IFN-gamma).

Authors:  A Wangoo; I N Brown; B G Marshall; H T Cook; D B Young; R J Shaw
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

4.  Macrophage functions in Biozzi mice.

Authors:  H M Dockrell; J Taverne; R Lelchuk; P Depledge; I N Brown; J H Playfair
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

5.  Characterization and specificity of B-cell responses in lupus induced by Mycobacterium bovis in NOD/Lt mice.

Authors:  A C Horsfall; R Howson; P Silveira; D G Williams; A G Baxter
Journal:  Immunology       Date:  1998-09       Impact factor: 7.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.